Skip to content

NeoGenomics NEO EPS (Basic)

EPS (Basic) at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$3.37+32.7%
Quest Diagnostics logo
Quest DiagnosticsDGX
$2.27+15.2%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$0.29-61.1%
Guardant Health logo
Guardant HealthGH
-$0.85-10.4%
Natera, Inc. logo
Natera, Inc.NTRA
-$0.60-20.0%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-$0.70-75.0%

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B+86.5%
Enterprise value$1.6B+159%
P/S2.3×+0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerBasicShare.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's EPS (basic)?
NeoGenomics (NEO) reported EPS (basic) of -$0.13 in Q1 2026.
How has NeoGenomics's EPS (basic) changed year-over-year?
NeoGenomics's EPS (basic) increased by 35.0% year-over-year, from -$0.20 to -$0.13.
What is the long-term trend for NeoGenomics's EPS (basic)?
Over 4 years (2021 to 2025), NeoGenomics's EPS (basic) has grown at a 85.6% compound annual growth rate (CAGR), from -$0.07 to -$0.83.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.